Full Press Release Details
In an exclusive interview on NPR’s “All Things Considered”, Dr. Howard Weiner shared promising results from the first patient, Joe Walsh, who received the treatment. Mr. Walsh, accompanied by his wife Karen, underwent a transformative experience at Brigham and Women’s Hospital, Boston, MA, where he received a monoclonal antibody via nasal administration. Intranasal foralumab, targets immune cells in the brain to mitigate inflammation, a key contributor to Alzheimer’s progression.
“I’ve never seen anything like this, and we’ve tried a lot of things. So I think this is something special,” stated Dr. Howard Weiner. “The reduction in brain inflammation observed in Joe Walsh represents a significant step forward in our understanding and treatment of Alzheimer’s disease. We are witnessing remarkable progress with foralumab.”
Karen Walsh, Joe’s wife and steadfast supporter, recounted their journey from diagnosis to participation in the clinical trial. “It’s been a rollercoaster,” she shared. “Since Joe started the treatment, we’ve noticed him becoming more engaged and enjoying social activities again.”